ARID5B and bladder transitional cell carcinoma: Additionally, mutations in ARID1A were frequent in bladder urothelial carcinoma (BLCA), UCEC, LUAD, and lung squamous cell carcinoma (LUSC), while ARID5B mutations were prevalent in UCEC (10%).